SNSE Faeth Therapeutics, Inc.: institutional ownership and insider trading
Over the last 12 months insiders bought $2.53M and sold $2.28M on the open market.
SNSE revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$16.0M, EPS -2.84
- Quarter ended Mar 31, 2026: revenue n/a, net income −$170M, EPS -131.45
- Quarter ended Dec 31, 2025: revenue n/a, net income −$4.72M, EPS -3.74
- Quarter ended Sep 30, 2025: revenue n/a, net income −$4.57M, EPS -3.62
Recent SNSE insider trades
- Jul 1, 2026: Stephenson Brian C bought 13,634 shares ($326K)
- Jun 26, 2026: Stephenson Brian C bought 15,641 shares ($401K)
- Jun 23, 2026: Stephenson Brian C bought 17,413 shares ($406K)
- Jun 22, 2026: Parikh Anand Kiran bought 2,806 shares ($55.4K)
5%+ owners
- VK Services, LLC: 10.2% (Schedule 13G, filed Aug 14, 2026)
- S2G Investments, LLC: 10.0% (Schedule 13G, filed Jun 23, 2026)
- Millennium Management LLC: 9.6% (Schedule 13G, filed May 15, 2026)
- Suvretta Capital Management, LLC: 7.8% (Schedule 13G, filed Jun 23, 2026)